North America Molecular Diagnostics Market Size Is Predicted To Reach $8.10 Billion By 2025

The North America Molecular Diagnostics (MDx) market size is expected to reach USD 8.10 billion by 2025 expanding at a CAGR of 10.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of long-term diseases, such as cancer, Cardiovascular Diseases (CVDs), neurological disorders, obesity, and diabetes, is expected to drive the North America MDx market.

According to the Population Reference Bureau, in U.S., the number of people aged 65 years and older is estimated to increase from 46 million in 2016 to around 98 million by 2060. Moreover, the data published by WHO states that the life expectancy is now exceeding to 80 years in most of the developed countries in the region. Thus, growing geriatric population is also likely to augment the market development. Aging characterizes the single most substantial risk factor for cancer development.

Based on the U.S. National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in individuals above the age of 65 years. This is where molecular diagnostics plays an important role as it has a tremendous impact on the management of suffering from chronic diseases such as cancer and Cardiovascular Diseases (CVDs). It is also vital for public health surveillance and detection.

Growing need for easy access to MDx has driven the Point-of-Care (PoC) market. One of the advantages offered by molecular diagnostics is that it can detect a disease even before the patient becomes symptomatic. PoC devices offer fast results, which, in turn, helps start treatments before the disease grows. With respect to infectious disease, early diagnosis can reduce pain, recovery time, and stop or slower the spread of disease.

Full Research Report On North American Molecular Diagnostics Market Visit Here: https://www.grandviewresearch.com/industry-analysis/north-america-molecular-diagnostics-market

Further key findings from the study suggest:

• Reagents led the North America molecular diagnostics market in 2017 owing to high number of R&D activities pertaining to self-test and PoC products
• Central laboratories held the largest revenue share in 2017 due to factors, such as availability of skilled labor and well-established infrastructure
• PoC segment is estimated to witness lucrative growth over the forecast period owing to rising healthcare awareness and demand for bedside testing
• Infectious diseases segment was the largest application segment in 2017 owing to increased cases of tuberculosis, pneumonia, HIV, and others
• Oncology segment is estimated to witness the fastest growth during the forecast period as it involves a number of diseases with unmet clinical needs for improved therapeutics and diagnostics
• Key companies are Roche Diagnostics; Qiagen N.V.; Danaher Corp.; Hologic, Inc; Johnson & Johnson; Becton, Dickinson and Company; Abbott Laboratories; bioMérieux SA; Illumina, Inc.; Novartis AG; and Cepheid, Inc.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/north-america-molecular-diagnostics-market/request/rs1

Grand View Research has segmented the North America molecular diagnostics market on the basis of product, test location, technology, application, and region:

North America MDx Product Outlook (Revenue, USD Million, 2014 - 2025)

• Instruments
• Reagents

North America MDx Test Location Outlook (Revenue, USD Million, 2014 - 2025)

• Point-of-Care (PoC)
• Self-test or Over the Counter (OTC)
• Central Laboratories

North America MDx Technology Outlook (Revenue, USD Million, 2014 - 2025)

• Polymerase Chain Reaction (PCR)
• Multiplex PCR
• Other PCR
• In Situ Hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and Microarrays
• Mass Spectrometry
• Sequencing
• Transcription Mediated Amplification
• Others

North America MDx Application Outlook (Revenue, USD Million, 2014 - 2025)

• Oncology
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Kidney Cancer
• Liver Cancer
• Blood Cancer
• Lung Cancer
• Other Cancer
• Pharmacogenomics
• Infectious Diseases
• Methicillin-resistant Staphylococcus Aureus (MRSA)
• Clostridium Difficile
• Vancomycin-resistant Enterococci (VRE)
• Carbapenem-resistant Bacteria
• Flu
• Respiratory Syncytial Virus (RSV)
• Candida
• Tuberculosis and drug-resistant TBA
• Meningitis
• Gastrointestinal Panel Testing
• Chlamydia
• Gonorrhea
• HIV
• Hepatitis C
• Hepatitis B
• Other Infectious Disease
• Genetic Testing
• Newborn Screening
• Predictive and Presymptomatic Testing
• Other Genetic Testing
• Neurological Disease
• Cardiovascular Disease
• Microbiology
• Others

North America MDx Regional Outlook (Revenue, USD Million, 2014 - 2025)

• U.S.
• Canada

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com